Key result
Intravenous iron administration during hospitalization for acute heart failure did not modify the one-year risk of death or readmission in patients with HFpEF and iron deficiency.
Why the study?
Heart failure with preserved ejection fraction is the most prevalent heart failure phenotype, and iron deficiency is a frequent comorbidity associated with poor prognosis.
Does intravenous iron reduce the one-year risk of readmission for acute HF or all-cause death in patients hospitalized with acute HFpEF and iron deficiency?
Cohort (n=467)
No
Does intravenous iron reduce the one-year risk of readmission for acute HF or all-cause death in patients hospitalized with acute HFpEF and iron deficiency?
Answers are grounded in this paper and cite their sources.
Intravenous iron administration during an acute hospital stay for HFpEF did not significantly reduce the one-year risk of death or heart failure readmission.
Background: Heart failure (HF) with preserved ejection fraction (HFpEF) is the most prevalent HF phenotype. Iron deficiency (ID), a frequent comorbidity, is associated with a poor prognosis. Methods: HFpEF patients included in the prospective acute HF registry of Geneva University Hospitals were included. Patients who received intravenous (IV) iron during the hospital stay were compared with those who did not using a COX proportional hazard model adjusting for baseline imbalances and prognostic factors. The primary endpoint was one-year risk of readmission for acute HF or all-cause death. Results: We included 467 patients (mean age 78 years, 49 % women). ID was present in 251 (54 %). IV iron was administered to 57 patients (22.7 %). Anaemia was present in 69 % of substituted versus 36 % of non-substituted patients (p < 0.01). One-year risk of death or HF-related rehospitalization was 46 % in substituted versus 43 % in non-substituted patients (p = 0.71). The hazard ratio of occurrence of the primary endpoint with IV iron administration was 1.08 (95 % CI 0.66-1.76) after adjustment for age, sex, body mass index, diabetes, chronic renal failure, chronic anaemia, NYHA class, NT-proBNP, plasma sodium, and estimated glomerular filtration rate. Conclusion: ID was highly prevalent in hospitalized patients with acute HF, and most patients were not substituted. IV iron administration during the acute stay did not modify one-year risk of death or readmission for acute HF.
No takes yet. Share an insight, caveat, or question.
Viviane et al. (2025) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) and iron deficiency (n=467). Intravenous iron vs. No intravenous iron was evaluated on One-year risk of readmission for acute HF or all-cause death (HR 1.08, 95% CI 0.66-1.76, p=0.75). Intravenous iron administration during hospitalization for acute heart failure did not modify the one-year risk of death or readmission in patients with HFpEF and iron deficiency.
Synapse has enriched 10 related papers. Consider them for comparative context: